EP Patent

EP4616867A1 — Combination of endothelin receptor antagonist and glucocorticoid for treating iga nephropathy

Assigned to Chinook Therapeutics Inc · Expires 2025-09-17 · 1y expired

What this patent protects

The present invention relates to a method of treating IgA nephropathy, and to a pharmaceutical composition comprising an endothelin receptor antagonist and a glucocorticoid.

USPTO Abstract

The present invention relates to a method of treating IgA nephropathy, and to a pharmaceutical composition comprising an endothelin receptor antagonist and a glucocorticoid.

Drugs covered by this patent

Patent Metadata

Patent number
EP4616867A1
Jurisdiction
EP
Classification
—
Expires
2025-09-17
Drug substance claim
No
Drug product claim
No
Assignee
Chinook Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.